APTX - Aptinyx Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.0720 |
| Open | 0.0703 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 900 |
| Day's Range | 0.0700 - 0.0758 |
| 52 Week Range | 0.0500 - 0.7390 |
| Volume | |
| Avg. Volume | 4,205,365 |
| Market Cap | 4.832M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0100 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.50 |
Fair Value
Related Research
ZacksHorizon (HZNP) Q1 Earnings and Revenues Miss Estimates
Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.
ZacksAnixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
ZacksAgenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug
The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.
ZacksAdaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
ZacksMerck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.
ZacksSeagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Business WireAptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
EVANSTON, Ill., March 30, 2023--Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.
ZacksHere's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Zacks
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
ZacksVertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
- Zacks
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
ZacksCOYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
ZacksMirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
ZacksSeagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
BenzingaWithin Six Months Aptinyx's Another Development Candidate Goes Up In Smoke
Aptinyx Inc (NASDAQ: APTX) announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over the placebo on the study's efficacy endpoints. The results do not support further development of NYX-458 by the company. The Phase 2 study enrolled 99 patients. The study evaluated
Business WireAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
EVANSTON, Ill., February 27, 2023--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over pl
Business WireAptinyx to Present at the SVB Securities Global Biopharma Conference
EVANSTON, Ill., January 31, 2023--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
Insider Monkey12 Best Biotech Stocks to Buy Under $10
In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10. The past two years have been challenging for the biotech sector, based on the market performance of biotech equities. Compared to […]
Business WirePreclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
EVANSTON, Ill., November 10, 2022--Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic
Business WireAptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
EVANSTON, Ill., November 08, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
Business WireClinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
EVANSTON, Ill., November 03, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD). NYX-783 is an NMDA receptor positive allosteric modulator also in P
Business WireAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
EVANSTON, Ill., October 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.
Insider Monkey10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners
In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl. To skip our analysis of Jeffrey Diehl’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners. Jeffrey […]
Business WireAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
EVANSTON, Ill., August 25, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety
Simply Wall St.Bullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k bet
Insiders who acquired US$567k worth of Aptinyx Inc.'s ( NASDAQ:APTX ) stock at an average price of US$2.34 in the past...